Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome

Journal of Gene Medicine

Volumn 12, Issue 6, 2010, Pages 481-490

  Li, Jiong ^a   Li, Xia ^a   Zhang, Yan ^a   Zhou, Xi K ^a   Yang, Han S ^a   Chen, Xian C ^a   Wang, Yong S ^a   Wei, Yu Q ^a   Chen, Li J ^a   Hu, Huo Z ^a   Liu, Chang Y ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antipsoriatic efficacy; Gene therapy; Interleukin 4; LacZ; Topical transdermal delivery; Ultradeformable cationic liposome

Indexed keywords

BETA GALACTOSIDASE; GENOMIC DNA; INTERLEUKIN 4; LIPOSOME; PLASMID DNA; VASCULOTROPIN; CATION; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EPIDERMIS; FEMALE; GENE TARGETING; GENE THERAPY; HAIR FOLLICLE; HISTOLOGY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; TRANSGENIC MOUSE; ANIMAL; CHEMISTRY; EAR; GENETICS; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SYNTHESIS; VASCULARIZATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CATIONS; EAR; FEMALE; GENETIC THERAPY; HUMANS; INTERLEUKIN-4; LIPOSOMES; MICE; MICE, TRANSGENIC; PARTICLE SIZE; PSORIASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954617245     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1459     Document Type: Article

References (37)

1. Krueger G, Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53: S94-S100. (Pubitemid 40828186)
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
3. Tonel G, Conrad C. Interplay between keratinocytes and immune cells - recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009; 41: 963-968.
4. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
5. MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med 2007; 83: 690-697.
6. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Haematol 2001; 15: 677-691.
7. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
8. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49: S87-S97.
9. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49: S98-104.
10. Asadullah K, Friedrich M, Hanneken S, et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 2001; 116: 721-727.
11. Asadullah K, Sterry W, Stephamek K, et al. IL-10 is a key cytokine in psoriasis. Proof principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-794.
12. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003; 49: S105-S111.
13. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49: S112-S117.
14. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 2004; 17: 427-431.
15. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb P. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
16. Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40-46.
17. Boehncke WH, Schon MP. Animal models of psoriasis. Clin Dermatol 2007; 25: 596-605.
18. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161-168. (Pubitemid 36759650)
19. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3: 115-124. (Pubitemid 38239773)
20. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004; 9: 697-703.
21. Zaffaroni A. Overview and evolution of therapeutic systems. Ann NY Acad Sci 1991; 618: 405-421.
22. KarandeP, JainA, MitragotriS. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol 2004; 22: 192-197.
23. Yu WH, Kashani-Sabet M, Liggitt D, Moore D, Heath TD, Debs RJ. Topical gene delivery to murine skin. J Invest Dermatol 1999; 112: 370-375.
24. Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol 2002; 54: 1609-1614.
25. Lee EH, Kim A, Oh YK, Kim CK. Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials 2005; 26: 205-210.
26. Domashenko A, Gupta S, Cotsarelis G. Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat Biotechnol 2000; 18: 420-423.
27. BirchallJC, MarichalC, CampbellL, AlwanA, HadgraftJ, Gumbleton M. Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposomeplasmid DNA complexes. Int J Pharm 2000; 197: 233-238.
28. Kim A, Lee EH, Choi SH, Kim CK. In vitro and in vivo transfection efficiency of a novel ultradeformable cationic liposome. Biomaterials 2004; 25: 305-313.
29. Baker BS, Brent L, Valdimarsson H, et al. Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines? Br J Dermatol 1992; 126: 105-110.
30. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87-99.
31. Kang MJ, Kim CK, Kim MY, et al. Skin permeation, biodistribution, and expression of topically applied plasmid DNA. J Gene Med 2004; 6: 1238-1246.
32. Raghavachari N, Fahl WE. Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles. J Pharm Sci 2002; 91: 615-622.
33. Liu LJ, Watabe S, Hamajima K, et al. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. Vaccine 2001; 20: 42-48.
34. Groves RW, Allen MH, Barker JN, Haskard DO, MacDonald DM. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol 1991; 124: 117-123.
35. Groves RW, Ross EL, Barker JN, MacDonald DM. Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon gamma. J Am Acad Dermatol 1993; 29: 67-72.
36. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20: 617-629.
37. Yazici AC, Tursen U, Apa DD, et al. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res 2005; 297: 249-255.